Remidio, RetinaRisk partner to improve AI-driven Diabetic Retinopathy Screening

This partnership brings together Remidio’s Medios DR AI for automated DR detection and RetinaRisk’s personalised risk triaging algorithm for progression to sight-threatening DR. Medios DR is an edge-AI solution that runs entirely on a smartphone without the need for internet access or cloud connectivity, offering real-time DR grading at the point of care. RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status.